Compounds of formula (I), wherein Ar?1 and Ar2¿ are independently phenyl unsubstituted or substituted by halogen, hydroxy, thiol, lower alkoxy, lower thioalkyl, lower alkanoyloxy, lower alkyl, nitro, amino, lower S(O)¿n?-alkyl wherein n is 0, 1, or 2, sulfonamide or trifluoromethyl; or a heteroaryl selected from 2- or 3-thienyl or 2- or 3-furanyl wherein the thienyl or furanyl is unsubstituted or substituted by lower alkyl, or halogen; with the overall proviso that at least one of Ar?1 or Ar2¿ is the heteroaryl and that both of Ar?1 and Ar2¿ cannot have more than one substitution; R¿2?', R3', and R5' are each independently hydrogen, alkanoyl having two to twelve carbon atoms in a straight or branched alkyl chain which may be substituted by amino, benzoyl or benzoyl substituted by lower alkyl, lower alkoxy, halogen or trifluoromethyl; additionally, R2' and R3' may be linked together to form a five-membered alkylidene ring having a total of up to twenty carbons such as, for example, isopropylidene, or a cyclic phosphate ester and R5' may be a phosphate, hydrogen or dihydrogen phosphate, or an alkali metal or ammonium or dialkali or diammonium salt thereof, such as, for example, PO3Na2. The novel 2- or 3-thienyl and 2- or 3-furanyl derivatives of adenosines of the present invention provide very potent A1 and A2 selective receptor binding activity. Particularly, the present invention provides highly active antipsychotic and advantageous cardiovascular effects.
展开▼
